CIK 0001894562 · <br>Emerging growth company
Prime Medicine, Inc.
Sign in to watch- Ticker
- PRME
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-465-0013
- Business address
- 60 FIRST ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-18 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −14,022 | $13.06 | $183K | 0 |
| 2023-05-17 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −15,000 | $12.77 | $192K | 10,735,324 |
| 2023-05-16 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −50,649 | $12.59 | $638K | 10,750,324 |
| 2023-05-15 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −157,952 | $12.74 | $2.0M | 10,800,973 |
| 2023-05-12 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −27,290 | $12.72 | $347K | 10,958,925 |
| 2023-05-11 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −21,819 | $12.98 | $283K | 10,991,022 |
| 2023-05-11 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −4,807 | $13.79 | $66K | 10,986,215 |
| 2023-05-10 | Marrazzo Jeffrey D Director | Grant or award · Stock Option (right to buy) | +92,000 | 92,000 | ||
| 2023-05-10 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −87,397 | $14.03 | $1.2M | 11,012,841 |
| 2023-05-09 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −321,238 | $14.08 | $4.5M | 11,100,238 |
| 2023-05-08 | GV 2019 GP, L.L.C. 10% owner | Sale 10b5-1 | −100,772 | $14.13 | $1.4M | 11,421,476 |
| 2023-04-18 | Alenson Carman See Remarks | Grant or award · Stock Option (right to buy) | +6,254 | 6,254 | ||
| 2023-04-18 | Goldwasser Meredith SVP, Strategy & Corporate Ops. | Grant or award · Stock Option (right to buy) | +4,690 | 4,690 | ||
| 2023-03-31 | Goldwasser Meredith SVP, Strategy & Corporate Ops. | Grant or award · Stock Option (right to buy) | +90,498 | 90,498 | ||
| 2023-03-31 | Duffield Jeremy Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +180,995 | 180,995 | ||
| 2023-03-31 | Brudnick Richard Chief Business Officer | Grant or award · Stock Option (right to buy) | +135,747 | 135,747 | ||
| 2023-03-31 | Gottesdiener Keith Michael See Remarks | Grant or award · Stock Option (right to buy) | +497,738 | 497,738 | ||
| 2023-03-31 | LEE ANN L. Chief Technical Officer | Grant or award · Stock Option (right to buy) | +180,995 | 180,995 | ||
| 2023-03-31 | Alenson Carman See Remarks | Grant or award · Stock Option (right to buy) | +90,498 | 90,498 | ||
| 2022-10-24 | GV 2019 GP, L.L.C. 10% owner | Conversion | +10,722,248 | 10,722,248 |
Page 10 of 13 · 241 trades